T cells and liver fibrosis
Portal Hypertension & Cirrhosis · 2022
DOI: 10.1002/poh2.11 ↗Kurz gefasst
Fachartikel in der Zeitschrift Portal Hypertension & Cirrhosis, 2022. Verfasst von Ruonan Sun und 2 weiteren Autor:innen. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Liver fibrosis develops from the excessive deposition of extracellular matrix in the liver caused by chronic liver inflammation or various chronic injuries, and it eventually develops into liver cirrhosis. The process of liver fibrosis is closely related to the immune response, and increasing evidence reveals the role of T lymphocytes, including Th1, Th2, Th17, regulatory T cells, and mucosa‐associated invariant T cells, in liver fibrosis. These immune cells play antifibrotic or profibrotic roles during fibrosis, and the reversal of fibrosis by targeting immune cells has attracted widespread attention. Activation of hepatic stellate cells, which form the core of fibrosis, is regulated by various immune mediators, including various immune cells and their associated cytokines. Therefore, the mechanism of action elicited by each cell type must be further elucidated to provide a basis for the design of new therapeutic targets. The purpose of this review is to summarize the roles and mechanisms of T lymphocytes and their subsets in liver fibrosis and highlight the biomarkers and potential therapeutic targets associated with these cells.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Sun, R., Xiang, Z., & Wu, B. (2022). T cells and liver fibrosis. Portal Hypertension & Cirrhosis. https://doi.org/10.1002/poh2.11
Vancouver
Sun R, Xiang Z, Wu B. T cells and liver fibrosis. Portal Hypertension & Cirrhosis. 2022. doi:10.1002/poh2.11
BibTeX
@article{Sun2022,
author = {Sun, Ruonan and Xiang, Zheng and Wu, Bin},
title = {T cells and liver fibrosis},
journal = {Portal Hypertension & Cirrhosis},
year = {2022},
doi = {10.1002/poh2.11}
}
EUVIMED